Showing results (181-190 of 1,541) with videos related to
Sort By:
Pageof 155
Cancer Reports (Hoboken, N.J.)|September 3, 2021
Tracheal chondrosarcoma: A case report, systematic review, and pooled analysisMitchell Heuermann, Simon Bekker, Thomas Czeczok, et al.Cancer Reports (Hoboken, N.J.)|August 19, 2021
The risks associated with the widespread use of telemedicine in oncology: Four cases and review of the literatureFrançois Panet, Marianne Tétreault-Langlois, Vincent Morin, et al.Cancer Reports (Hoboken, N.J.)|May 25, 2021
Impact of pathological response after neoadjuvant chemotherapy on adjuvant therapy decisions and patient outcomes in gastrointestinal cancersSheena Bhalla, Huili Zhu, Jung-Yi Lin, et al.Cancer Reports (Hoboken, N.J.)|February 8, 2023
Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinibCass G G Sunga, Michael S Higgins, Robert W Ricciotti, et al.Cancer Reports (Hoboken, N.J.)|November 16, 2022
Association of genetic variants and survival in patients with acute myeloid leukemia in rural AppalachiaCarl Shultz, Christopher Gates, William Petros, et al.Cancer Reports (Hoboken, N.J.)|November 20, 2025
Development of a Predictive Model for Large-Volume Pleural Effusion After Separation Surgery in Patients With Spinal Metastatic TumorsHaochen Mou, Keyi Wang, Hao Qu, et al.Cancer Reports (Hoboken, N.J.)|November 26, 2025
Brain Metastases in Cervical Cancer: A Global Systematic Review and Meta-Analysis of Incidence and Clinicopathological FeaturesKimia Pakdaman, Amirhossein Alizadeh-Nodehi, Amir-Hossein Lashkarbolouki, et al.Cancer Reports (Hoboken, N.J.)|November 27, 2025
Peripheral Blood CD4/CD8 Ratio Predicts Out-of-Specification Products in Lisocabtagene Maraleucel ManufacturingTaichi Hirano, Hiro Tatetsu, Shikiko Ueno, et al.Cancer Reports (Hoboken, N.J.)|November 27, 2025
The Evaluation of Diagnostic, Prognostic, and Predictive Role of Hematologic Inflammatory Indices NLR, PLR, and LMR in Common Solid TumorsFatemeh Arianmanesh, Saeede Bagheri, Mohammad Ali Karimi, et al.Cancer Reports (Hoboken, N.J.)|January 9, 2026
Real-World Outcomes With Low-Dose Dasatinib (50 mg) in Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Analysis of Efficacy and SafetyNandhini Gangadaran, Harshal Mamlekar, Souvik Saha, et al.Pageof 155